Rock Springs Capital Management LP Has $13.93 Million Position in Heartflow, Inc. $HTFL

Rock Springs Capital Management LP increased its position in shares of Heartflow, Inc. (NASDAQ:HTFL) by 106.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 572,500 shares of the company’s stock after buying an additional 294,800 shares during the quarter. Rock Springs Capital Management LP’s holdings in Heartflow were worth $13,929,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of HTFL. TrueMark Investments LLC grew its stake in shares of Heartflow by 1.4% during the 1st quarter. TrueMark Investments LLC now owns 26,885 shares of the company’s stock worth $654,000 after acquiring an additional 379 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Heartflow in the fourth quarter worth $27,000. Strs Ohio boosted its holdings in Heartflow by 35.3% during the first quarter. Strs Ohio now owns 4,600 shares of the company’s stock worth $112,000 after purchasing an additional 1,200 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Heartflow during the fourth quarter worth $45,000. Finally, Legal & General Group Plc bought a new position in Heartflow in the third quarter valued at $59,000.

Insider Transactions at Heartflow

In other news, CEO John C.M. Farquhar sold 22,562 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $27.75, for a total value of $626,095.50. Following the transaction, the chief executive officer owned 435,373 shares of the company’s stock, valued at approximately $12,081,600.75. This represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $29.23, for a total value of $27,732,167.11. Following the transaction, the insider owned 8,448,158 shares in the company, valued at approximately $246,939,658.34. This trade represents a 10.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,861,695 shares of company stock worth $54,692,848 over the last quarter. Company insiders own 7.70% of the company’s stock.

Heartflow Stock Performance

NASDAQ HTFL opened at $25.37 on Tuesday. The stock has a market cap of $2.19 billion and a PE ratio of -8.16. The firm has a 50-day moving average of $29.24 and a 200-day moving average of $28.28. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $41.22.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The company had revenue of $52.59 million during the quarter. The company’s revenue for the quarter was up 41.3% on a year-over-year basis. As a group, analysts predict that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on HTFL shares. Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Piper Sandler restated an “overweight” rating on shares of Heartflow in a report on Thursday, June 11th. Stifel Nicolaus set a $40.00 target price on Heartflow in a research report on Wednesday, July 15th. Wells Fargo & Company increased their price target on Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. Finally, Weiss Ratings downgraded Heartflow from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $37.00.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.